Madelaine Kuiper, MSN, NP, Discusses Rapid Development of HER2-Targeted Therapies

December 24, 2019

The nurse practitioner from UCLA Health spoke about the expanding treatment options in this setting.

Madelaine Kuiper, MSN, NP, from UCLA Health, discussed the progression of HER2-positive breast cancer treatment at the San Antonio Breast Cancer Symposium, held December 10-14, in San Antonio, Texas.

Transcription:
You know look, honestly, from determining when Dr. Slamon first developed HER2 notification or amplification and then developing trastuzumab (Herceptin) to manage this disease, I mean it’s changed rapidly. I have to say, I do remember in the 80s when he was working on this stuff and when we were actually treating patients once approved, but even in the last, gosh, you know the last 6 years that I’ve been working with breast particularly, is the rapid development of HER2 targeted therapies, you know, with the development of trastuzumab emtansine (T-DM1) and then pertuzumab (Perjeta) and then the oral tucatinib, and now some of the later stuff with DS-8201 (trasuzumab deruxtecan), I mean it’s just amazing how many drugs are looking very positive in this setting and expanding treatment options for patients definitely.